Location：
Home >
Molecular Diagnosis >
Capture Probe

Capture Reagents

In recent years, methods such as target sequence capture and whole-exome capture enable cost-effective and efficient targeting of corresponding genomic regions. Moreover, the large number of DNA fragments generated by these methods is highly suitable for sequencing on next-generation sequencing platforms. The combination of these technologies has greatly improved the efficiency of research on genetic diseases. More than 200 papers applying these techniques to solve genetic diseases were published between 2009 and 2011. The main advantages of gene capture sequencing include the ability to sequence specific regions, effectively reducing sequencing costs, increasing sequencing depth, and more accurately identifying genetic variation information in targeted regions. Two factors need to be considered when constructing a hybridization-based target sequence capture system: probe length and probe synthesis cost. GeneRulor Co., Ltd. has developed a unique probe synthesis technology that allows rapid, high-yield synthesis of long probes. Its low cost and flexibility are highly advantageous for genomic capture of specific regions. The research and development cycle for early tumor diagnosis products is approximately 3 months, and the product line can be rapidly expanded according to market demand.

Capture Reagent Service Types

HPV 捕获试剂盒

HPV Capture Kit

HBV Capture Kit

Human Whole Exome Capture Kit

Human Cot-1 DNA

Custom Probe Design

Hybridization Capture Probe SynthesisService


Service Advantages

Reliable and Trustworthy Products: Own independent production base; manufactured in strict accordance with GMP standards; certified with quality management system.
Reliable and Experienced Team: Supported by multiple postdoctoral researchers; most team members have more than 5 years of experience in in vitro diagnostic system development, with profound expertise in raw material R&D and performance evaluation, enabling rapid response to customized requirements.

Reliable Technology with Complete Patents: GeneRulor Co., Ltd. has applied for more than 40 patents, including patents for probe synthesis technology featuring high speed and high yield. The R&D cycle for early tumor diagnosis products is approximately 3 months, and the product line can be rapidly expanded according to market demand.

Tel：+86 15336557985
E-Mail：service@generulor.com
Micromessenger
Scan to consult
Linkedin
LIN HUABING
Teams：15022705442@163.com